{"id":688007,"date":"2022-09-22T08:10:52","date_gmt":"2022-09-22T12:10:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-2022-funding-recipients-of-patients-at-the-heart-and-progress-at-the-heart-award-programs\/"},"modified":"2022-09-22T08:10:52","modified_gmt":"2022-09-22T12:10:52","slug":"harmony-biosciences-announces-2022-funding-recipients-of-patients-at-the-heart-and-progress-at-the-heart-award-programs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-2022-funding-recipients-of-patients-at-the-heart-and-progress-at-the-heart-award-programs\/","title":{"rendered":"HARMONY BIOSCIENCES ANNOUNCES 2022 FUNDING RECIPIENTS OF PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD PROGRAMS"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n PLYMOUTH MEETING, Pa.<\/span>
\n <\/span>, Sept. 22, 2022<\/span><\/span> \/PRNewswire\/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (NASDAQ: HRMY), a pharmaceutical company dedicated to\u00a0developing and commercializing innovative therapies for patients with rare neurological diseases, today announced on the fourth annual World Narcolepsy Day, the funding recipients of its Patients at the Heart<\/a>\u00a0and Progress at the Heart<\/a>\u00a0award programs.<\/p>\n

\n

\n
\n \"Harmony
\n <\/a>\n <\/p>\n<\/p><\/div>\n

The Patients at the Heart program, which launched in 2019, underscores Harmony’s ongoing commitment to support the comprehensive needs of people affected by rare neurological diseases. Over the last four years, the program has awarded numerous nonprofit organizations that are working to support and address the challenges of people living with sleep disorders and rare neurological diseases who experience excessive daytime sleepiness (EDS).<\/p>\n

In 2021, Harmony initiated the Progress at the Heart program. This award funds innovative programs that address health disparities and inequities in rare neurological disease and sleep disorder communities. Combined with the Patients at the Heart awards, total funding for these two programs has now increased to $380,000<\/span> in over the last four years.<\/p>\n

“Combining empathy with innovation to improve\u00a0the lives of people living with rare neurological diseases is a mission that drives everyone at Harmony Biosciences,” said Cate McCanless, Chief Corporate Affairs Officer. “In recognition of World Narcolepsy Day, we are pleased to announce this year’s recipients of the Patients at the Heart and Progress at the Heart award programs. This diverse group of organizations have each developed new and innovative patient-centric initiatives to help address the unique needs of people living with rare neurological diseases. We look forward to the positive impact these programs will create for patients, caregivers and communities.”<\/p>\n

The following organizations were chosen as the 2022 Patients at the Heart award recipients:<\/p>\n